| Bioactivity | PROTAC MLKL Degrader-2 is a PROTAC targeting MLKL (Mixed Lineage Kinase). PROTAC MLKL Degrader-2 consists of PROTAC target protein ligand PROTAC MLKL Degrader-2 (HY-169072), E3 ligase ligand Thalidomide (HY-14658) and PROTAC Linker N-Methylpiperazine (HY-78871), of which the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-N-methylpiperazine (HY-169074). PROTAC MLKL Degrader-2 exhibits antinecroptotic activity on human cell lines and effectively degrades MLKL in the HT-29 xenograft mouse model[1]. |
| Target | MLKL |
| Formula | C36H35N9O9S |
| Molar Mass | 769.78 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Li S, et al. Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis. J Med Chem. 2024 Sep 12;67(17):15353-15372. |
PROTAC MLKL Degrader-2
CAS: F: C36H35N9O9S W: 769.78
PROTAC MLKL Degrader-2 is a PROTAC targeting MLKL (Mixed Lineage Kinase). PROTAC MLKL Degrader-2 consists of PROTAC targ
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.